Freedom to Move…All Over the World
Clinically studied Serratrin offers a lower dose and faster efficacy than most of the top-selling joint comfort and mobility products on the market.
Serratrin is a novel, full-spectrum Boswellia serrata extract, standardized to ≥ 30% boswellic acids. It is derived from two different extracts of Boswellia and formulated for maximum benefits. Boswellia has been used in the Ayurvedic medicine tradition for thousands of years. Serratrin takes this tradition and scientifically improves it for modern day use.
Serratrin was developed by Laila Nutraceuticals, a division of Laila Group, India’s leading producer of herbal extracts. The Research Center is accredited by the Government of India, Department of Scientific and Industrial Research (DSIR) and has partnered with various universities in its PhD research projects. The Laila Impex Research Center also has partnerships with Georgetown University in Washington, D.C., Ohio State University Medical Center, University of Kansas Medical Center, University of California, Davis, and Vienna Medical College in Austria.
A powerful, targeted anti-inflammatory Serratrin works by supporting a healthy inflammation metabolism. It has been shown in preclinical research to down-regulate key mediators of inflammatory pain, including 5-Lipoxygenase, Leukotriene B4, Prostaglandin E2, and TNF-α.
Serratrin was also shown to:
The pentacyclic triterpenic acids, named boswellic acids (BAs), present in the gum resin of Boswellia serrata, are the main constituents responsible for its anti-inflammatory property. Suppression of LT synthesis by inhibiting 5-LOX is considered the primary mechanism underlying their anti-inflammatory effect. BAs are specific and non-redox inhibitors of 5-LOX, and they do not affect 12-LOX and COX activities
Serratrin is made from the gum resin of the Indian frankincense (Boswellia serrata) tree. Boswellia gum resin is also ttraditionally known as Indian olibanum, Salai guggul, and Sallaki in Sanskrit. The plant is native to much of India and the Punjab region that extends into Pakistan.
PLT Boswellia serrata materials are sourced in India from the states of Andhra Pradesh and Madhya Pradesh. The entire Boswellia serrata supply chain starts with deep, long-term relationships developed with the most trustworthy collectors and aggregators that have been decades in the making. In conjunction with the Indian forestry department, collectors are trained on sustainable gum tapping methods to maximize yield while maintaining the safety and health of the Boswellia serrata tree populations. Tapping locations on the tree bark, as well as the frequency of tapping, are carefully controlled to maintain good tree health.
In early 2022, PLT Health Solutions announced the commencement of a third-party sustainability audit program on Boswellia serrata trees in India by renowned botanical research consultancy Botanical Liaisons, LLC. The third-party audit program is based on a broad range of environmental, cultural and economic parameters
At PLT, we understand that proper stewardship of natural resources and social responsibility toward the communities that support our work is both the right thing to do and good business.
In a randomized controlled trial, Serratrin was compared to placebo and to another commercially available boswellia extract in healthy, ambulatory women and men aged 30-65 years. The primary outcome measure was an 80-meter fast-paced walk test. Secondary endpoints included a 30-second chair stand test, VAS, WOMAC A (pain), WOMAC B (stiffness), WOMAC C (physical function), and primary knee flexion range of motion.
80-Meter Fast-Paced Walk Test
Serratrin showed significant improvement in the 80-meter fast-paced walk test as early as 7 days over placebo.
Serratrin showed significant improvement in the 30-second chair stand test as early as 7 days compared with placebo.
VAS Score
Serratrin significantly improved Mean VAS score as early as 7 days.
Serratrin significantly improved Average WOMAC scores as early as 7 days compared to placebo.
Clinically studied Serratrin offers a lower dose and faster efficacy than most of the top-selling joint comfort and mobility products on the market.